Please use this identifier to cite or link to this item:
https://doi.org/10.18632/oncotarget.12251
Title: | Targeting SALL4 by entinostat in lung cancer | Authors: | Yong, K.J Li, A Ou, W.-B Hong, C.K.Y Zhao, W Wang, F Tatetsu, H Yan, B Qi, L Fletcher, J.A Yang, H Soo, R Tenen, D.G Chai, L |
Keywords: | entinostat epidermal growth factor receptor SALL4 protein somatomedin C receptor tumor protein unclassified drug antineoplastic agent benzamide derivative entinostat histone deacetylase inhibitor pyridine derivative SALL4 protein, human small interfering RNA transcription factor adult Article cancer growth cancer survival controlled study disease activity drug effect drug mechanism drug targeting female human lung cancer lung carcinogenesis major clinical study male molecular pathology protein determination protein expression protein function RNA interference signal transduction survival rate animal antagonists and inhibitors cell survival disease model drug screening gene expression genetics lung tumor mouse tumor cell line Animals Antineoplastic Agents Benzamides Cell Line, Tumor Cell Survival Disease Models, Animal Gene Expression Histone Deacetylase Inhibitors Humans Lung Neoplasms Mice Pyridines RNA Interference RNA, Small Interfering Transcription Factors Xenograft Model Antitumor Assays |
Issue Date: | 2016 | Citation: | Yong, K.J, Li, A, Ou, W.-B, Hong, C.K.Y, Zhao, W, Wang, F, Tatetsu, H, Yan, B, Qi, L, Fletcher, J.A, Yang, H, Soo, R, Tenen, D.G, Chai, L (2016). Targeting SALL4 by entinostat in lung cancer. Oncotarget 7 (46) : 75425-75440. ScholarBank@NUS Repository. https://doi.org/10.18632/oncotarget.12251 | Abstract: | The overall survival of lung cancer patients remains dismal despite the availability of targeted therapies. Oncofetal protein SALL4 is a novel cancer target. We herein report that SALL4 was aberrantly expressed in a subset of lung cancer patients with poor survival. SALL4 silencing by RNA interference or SALL4 peptide inhibitor treatment led to impaired lung cancer cell growth. Expression profiling of SALL4-knockdown cells demonstrated that both the EGFR and IGF1R signaling pathways were affected. Connectivity Map analysis revealed the HDAC inhibitor entinostat as a potential drug in treating SALL4-expressing cancers, and this was confirmed in 17 lung cancer cell lines. In summary, we report for the first time that entinostat can target SALL4-positive lung cancer. This lays the foundation for future clinical studies evaluating the therapeutic efficacy of entinostat in SALL4-positive lung cancer patients. | Source Title: | Oncotarget | URI: | https://scholarbank.nus.edu.sg/handle/10635/174105 | ISSN: | 19492553 | DOI: | 10.18632/oncotarget.12251 |
Appears in Collections: | Elements Staff Publications |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_18632_oncotarget_12251.pdf | 5.42 MB | Adobe PDF | OPEN | None | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.